This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01019-07v1 52/3/1150    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rueda, C. Articles by del Aguila, C. Search for Related Content PubMed PubMed Citation Articles by Rueda, C. Articles by del Aguila, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 1150-1152, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01019-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Bobel-24 Activity against Cryptosporidium parvum in Cell Culture and in a SCID Mouse Model

Sección de Parasitología, Departamento de Bioquímica, Biología Celular y Molecular, Facultad de Farmacia, Universidad San Pablo CEU, Urbanización Montepríncipe, Ctra. Boadilla del Monte km 5,300, 28668 Madrid, Spain,¹ Departamento de Parasitología, Facultad de Farmacia, Universidad de Salamanca, Salamanca, Spain²

Received 2 August 2007/ Returned for modification 24 October 2007/ Accepted 16 December 2007

The anticryptosporidial activity of Bobel-24 (2,4,6-triiodophenol) was studied for the first time, resulting in a reduction of the in vitro growth of Cryptosporidium of up to 99.6%. In a SCID mouse model of chronic cryptosporidiosis, significant differences (P < 0.05) in oocyst shedding were observed in animals treated with 125 mg/kg/day. These results merit further investigation of Bobel-24 as a chemotherapeutic option for cryptosporidiosis.

Published ahead of print on 26 December 2007.